AR106660A1 - CELLULAR REDOX LEVEL CONTROL - Google Patents

CELLULAR REDOX LEVEL CONTROL

Info

Publication number
AR106660A1
AR106660A1 ARP160103444A ARP160103444A AR106660A1 AR 106660 A1 AR106660 A1 AR 106660A1 AR P160103444 A ARP160103444 A AR P160103444A AR P160103444 A ARP160103444 A AR P160103444A AR 106660 A1 AR106660 A1 AR 106660A1
Authority
AR
Argentina
Prior art keywords
drug
lysates
affects
bacterial
diuretic
Prior art date
Application number
ARP160103444A
Other languages
Spanish (es)
Original Assignee
Mckenna Elizabeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mckenna Elizabeth filed Critical Mckenna Elizabeth
Publication of AR106660A1 publication Critical patent/AR106660A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)

Abstract

Composiciones y métodos para regular el estado redox y/o reducir el estrés oxidativo en un sujeto, en donde los métodos y las composiciones comprenden agonistas de TLR que comprenden lisados y/o fracciones de lisados bacterianos. También composiciones y métodos que comprenden lisados y/o fracciones de lisados bacterianos formulados o administrados en combinación con uno o más agentes terapéuticos o farmacéuticos diferentes. Reivindicación 65: Un método para producir un lisado bacteriano que comprende las etapas de: (a) fermentar una bacteria en un medio de cultivo hasta la fase de cultivo estacionaria para producir un caldo de fermentación; (b) recolectar bacterias del caldo de fermentación; (c) pasteurizar las bacterias recolectadas; y (d) lisar las bacterias pasteurizadas con una lisozima para producir un lisado bacteriano. Reivindicación 70: Un lisado bacteriano producido de acuerdo con el método de cualquiera de las reivindicaciones 65 - 69. Reivindicación 100: La combinación terapéutica de acuerdo con la reivindicación 97 o la formulación farmacéutica de acuerdo con la reivindicación 99, en donde uno o más de los agentes farmacéuticos se seleccionan del grupo que consiste en: un antiespasmódico, un estimulante de la movilidad, un antagonista del receptor H2, un antimuscarínico; un quelato, un análogo de prostaglandina, un aminosalicilato, un corticoesteroide, un fármaco que afecta la respuesta inmunitaria, un laxante estimulante, un fármaco que afecta la composición y el flujo biliares, un secuestrante de ácidos biliares, un antagonista de dopamina, un inhibidor de la bomba de protones, un opioide, un antagonista del receptor de opioide, un analgésico, un somnífero, un glucósido cardíaco, un inhibidor de la fosfodiesterasa, una tiazida, un diurético, un diurético ahorrador de potasio, un antagonista de aldosterona, un diurético osmótico, un fármaco contra la arritmia, un fármaco bloqueador del adrenorreceptor beta, un fármaco contra la hipertensión, un fármaco que afecta el sistema renina- angiotensina, un nitrato, un bloqueador de calcio, un fármaco antianginoso, un vasodilatador periférico, un simpaticomimético, un anticoagulante, una protamina, un fármaco antiplaquetario, un fármaco fibrinolítico, un fármaco antifibrinolítico, un fármaco regulador de lípidos, un compuesto de ácidos grasos omega 3, un fármaco del SNC, un antiinfeccioso u otro fármaco seleccionado del grupo que consiste en benzatropina, prociclidina, biperideno, amantadina, bromocriptina, pergolida, entacapona, tolcapona, selegilina, pramipexol, budesónido, formoterol, fumarato de quetiapina, olanzapina, pioglitazona, montelukast, ácido zoledrónico, valsartán, latanoprost, irbesartán, clopidogrel, atomoxetina, dexanfetamina, metilfenidato, modafinilo, bleomicina, dactinomicina, daunorrubicina, idarrubicina, mitomicina, mitoxantrona, azacitidina, capecitabina, cladribina, clofarabina, citarabina, fludarabina, fluorouracilo, gemcitabina, mercaptopurina, metotrexato, nelarabina, pemetrexed, raltitrexed, tioguanina, apomorfina, betametasona, cortisona, deflazacort, dexametosona, hidrocortisona, metilprednisolona, prednisolona, triamcinolona, ciclosporina, sirolimus, tacrolimus, interferón a e interferón b. Reivindicación 104: El uso de la formulación de acuerdo con la reivindicación 103 en la fabricación de un medicamento para el tratamiento de la artritis reumatoide (RA), RA de aparición tardía o artritis psoriásica en un sujeto.Compositions and methods for regulating the redox state and / or reducing oxidative stress in a subject, wherein the methods and compositions comprise TLR agonists comprising lysates and / or fractions of bacterial lysates. Also compositions and methods comprising lysates and / or fractions of bacterial lysates formulated or administered in combination with one or more other therapeutic or pharmaceutical agents. Claim 65: A method of producing a bacterial lysate comprising the steps of: (a) fermenting a bacterium in a culture medium to the stationary culture phase to produce a fermentation broth; (b) collect bacteria from the fermentation broth; (c) pasteurize the collected bacteria; and (d) lyse the pasteurized bacteria with a lysozyme to produce a bacterial lysate. Claim 70: A bacterial lysate produced according to the method of any of claims 65-69. Claim 100: The therapeutic combination according to claim 97 or the pharmaceutical formulation according to claim 99, wherein one or more of Pharmaceutical agents are selected from the group consisting of: an antispasmodic, a mobility stimulant, an H2 receptor antagonist, an antimuscarinic; a chelate, a prostaglandin analogue, an aminosalicylate, a corticosteroid, a drug that affects the immune response, a stimulant laxative, a drug that affects bile composition and flow, a bile acid sequestrant, a dopamine antagonist, an inhibitor of the proton pump, an opioid, an opioid receptor antagonist, an analgesic, a sleeping pill, a cardiac glycoside, a phosphodiesterase inhibitor, a thiazide, a diuretic, a potassium-sparing diuretic, an aldosterone antagonist, a Osmotic diuretic, an anti-arrhythmia drug, a beta adrenoceptor blocking drug, an anti-hypertension drug, a drug that affects the renin-angiotensin system, a nitrate, a calcium blocker, an antianginal drug, a peripheral vasodilator, a sympathomimetic , an anticoagulant, a protamine, an antiplatelet drug, a fibrinolytic drug, an antifibrinolytic drug, a lipid regulating drug, a compound of omega 3 fatty acids, a CNS drug, an anti-infective or other drug selected from the group consisting of benzatropin, procyclidine, biperidene, amantadine, bromocriptine, pergolide, entacapone, tolcapone, selegiline, pramipexole, budesonide , formoterol, quetiapine fumarate, olanzapine, pioglitazone, montelukast, zoledronic acid, valsartan, latanoprost, irbesartan, clopidogrel, atomoxetine, dexamphetamine, methylphenidate, modafinil, bleomycin, dactinomycin, clauncinothinacin, daunorubin, cytoatrin, thiatrinitin, caprine, thromatin, cyprinitin, cycromatin, cycromatin clofarabine, cytarabine, fludarabine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, thioguanine, apomorphine, betamethasone, cortisone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, triamcinolone, cyclosporine, sirolimus, tacrolimus, interferon ae interferon b . Claim 104: The use of the formulation according to claim 103 in the manufacture of a medicament for the treatment of rheumatoid arthritis (RA), late onset RA or psoriatic arthritis in a subject.

ARP160103444A 2015-11-10 2016-11-10 CELLULAR REDOX LEVEL CONTROL AR106660A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562253542P 2015-11-10 2015-11-10

Publications (1)

Publication Number Publication Date
AR106660A1 true AR106660A1 (en) 2018-02-07

Family

ID=57530816

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103444A AR106660A1 (en) 2015-11-10 2016-11-10 CELLULAR REDOX LEVEL CONTROL

Country Status (13)

Country Link
EP (1) EP3373943A1 (en)
JP (2) JP2018532814A (en)
CN (1) CN108430482A (en)
AR (1) AR106660A1 (en)
AU (2) AU2016352986A1 (en)
BR (1) BR112018009437A2 (en)
CA (1) CA3004951A1 (en)
EA (1) EA201891142A1 (en)
HK (1) HK1252018A1 (en)
IL (1) IL259228A (en)
MX (1) MX2018005745A (en)
SG (2) SG11201803906PA (en)
WO (1) WO2017083470A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110468061B (en) * 2018-05-11 2024-03-08 韩国亿诺生物有限公司 Novel strain having cancer preventing or treating effect
CN108949640B (en) * 2018-08-22 2020-08-04 江南大学 Bifidobacterium breve CCFM1025, fermented food thereof and application thereof
CN109568320A (en) * 2018-12-13 2019-04-05 中国人民解放军总医院 Etravirine is preparing the application in antibacterial-anti-inflammatory drug
CN109912598B (en) * 2019-03-27 2022-09-13 四川大学华西医院 Nucleoside derivative for preventing and treating inflammatory reaction and application thereof
CN110106111B (en) * 2019-05-06 2021-04-02 华东理工大学 Preparation method of pseudomonas preparation, preparation product and application of preparation product
JP7369992B2 (en) * 2019-05-13 2023-10-27 株式会社明治 Fermented milk for improving autonomic nervous function
CN110079485B (en) * 2019-05-31 2020-09-25 江南大学 Pediococcus acidilactici CCFM6432 for relieving depression, fermented food thereof and application thereof
GB2601667B (en) * 2019-08-05 2023-01-25 Ibm Combination therapy to achieve enhanced antimicrobial activity
CN110604098B (en) * 2019-09-23 2021-09-07 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Method for constructing animal model of rheumatoid arthritis combined with interstitial lung disease
CN111849805B (en) * 2020-06-17 2022-04-22 天津科技大学 Pediococcus acidilactici with cervical cancer resistance effect and application thereof
CN117377480A (en) * 2020-10-14 2024-01-09 音芙医药科技(上海)有限公司 Application of nicotinamide mononucleotide and lactobacillus fermentum in preparation of preparation for relieving skin photoaging
CN113304155B (en) * 2021-05-24 2023-03-24 四川大学华西医院 Anti-tumor pharmaceutical composition and preparation method and application thereof
CN117915934A (en) * 2021-07-09 2024-04-19 C·德西蒙 Species, strains and compositions of lactic acid bacteria capable of modulating body oxygenation by increasing HIF-1 alpha levels
CN113528399B (en) * 2021-08-18 2023-02-10 兰州大学 Pediococcus acidilactici with hexavalent chromium ion reducing capacity and application thereof
CN113712953B (en) * 2021-10-20 2022-07-29 济宁医学院附属医院 Pharmaceutical composition for rapidly healing osteoporotic fracture
CN114381398B (en) * 2022-01-08 2022-06-14 浙江大学 Lactobacillus helveticus ZJUIDS12 capable of improving alcoholic liver disease and application thereof
CN115282151B (en) * 2022-08-23 2023-06-09 黑龙江护理高等专科学校 Application of lamitinuron
CN116042490B (en) * 2023-03-03 2023-09-01 善恩康生物科技（苏州）有限公司 Composite probiotics for resisting fatigue and improving exercise capacity as well as preparation method and application thereof
CN116286669B (en) * 2023-03-23 2023-09-22 江南大学 Hybridoma cell strain secreting toraset Mi Shan clone antibody and application thereof
CN116735756A (en) * 2023-08-08 2023-09-12 天津辰欣药物研究有限公司 Detection method for measuring 3-bromopropylamine hydrobromide impurity in peama Bei Teqi starting material by gas chromatography

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6632802B2 (en) * 2012-01-16 2020-01-22 マッケンナ，エリザベス Compositions and methods for treating liver diseases and disorders

Also Published As

Publication number Publication date
AU2023251534A1 (en) 2023-11-16
JP2023011830A (en) 2023-01-24
IL259228A (en) 2018-07-31
WO2017083470A1 (en) 2017-05-18
CN108430482A (en) 2018-08-21
EP3373943A1 (en) 2018-09-19
BR112018009437A2 (en) 2018-12-04
HK1252018A1 (en) 2019-05-10
SG11201803906PA (en) 2018-06-28
SG10202112466UA (en) 2021-12-30
JP2018532814A (en) 2018-11-08
CA3004951A1 (en) 2017-05-18
AU2016352986A1 (en) 2018-06-28
MX2018005745A (en) 2018-09-17
EA201891142A1 (en) 2018-11-30

Similar Documents

Publication Publication Date Title
AR106660A1 (en) CELLULAR REDOX LEVEL CONTROL
Aberg et al. Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice
SI3119794T1 (en) Formulation comprising a gemcitabine-prodrug
CA2945938C (en) Gemcitabine prodrugs
US20220273595A1 (en) Compositions and methods for treating eczema
CL2019001447A1 (en) Preparation of solid cyclodextrin complexes for the supply of ophthalmic active pharmaceutical ingredients.
AU2016375866B2 (en) Formulations of phosphoramidate derivatives of nucleoside drugs
NZ726256A (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
NZ739902A (en) Multiligand agent for drug delivery
CA3008749C (en) Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
CL2017000670A1 (en) Method and composition for producing improved anti-inflammatory / anti-catabolic regenerative agents from autologous physiological fluid
PE20170296A1 (en) PROCEDURE FOR MANUFACTURING A GLATIRAMER ACETATE PRODUCT
BR112021026374A2 (en) cbd composition
JP2016510329A5 (en)
SG11201809948XA (en) Method for producing celastrol and pentacyclic triterpene derivatives
AR090457A1 (en) SEMISOLID TOPIC COMPOSITION CONTAINING PYRFENIDONE AND DIALYL MODIFIED DISULFIDE OXIDE (ODD-M) TO ELIMINATE OR PREVENT ACNE
JP2017513809A5 (en)
BR112018012022A2 (en) ? composition, and method for treating or reducing the risk of intrahepatic cholestasis?
Snell et al. A randomized, double-blind, placebo-controlled, multicenter study of rabbit ATG in the prophylaxis of acute rejection in lung transplantation
WO2017070515A3 (en) Methods of preventing and treating inflammatory bowel disease with branched fatty acid esters of hydroxy fatty acids (fahfas)
US20100063015A1 (en) Skin-care preparations containing mupirocin and betamethasone dipropionate
WO2020018032A3 (en) Topical pharmaceutical formulations comprising pimecrolimus, clobetasol and calcipotriol for the treatment of psoriasis
CN106727366A (en) A kind of benzene sulphur is along the long-acting freeze-dried powder of atracurium
Fava et al. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant

Legal Events

Date Code Title Description
FB Suspension of granting procedure